Thus, altogether, direct MAPK inhibition by vemurafenib, indirect PI3K/AKT downregulation by PRIMA-1Met [36], and the supplemental effect by RT and PRIMA-1Met on p53 activation may explain the observed synergistic effect of the triplet BRAF inhibitor, p53 reactivator, and RT on BRAF mutant melanoma cells both in vitro and in vivo. This evidence concerns the gene BRAF and melanoma.